VERU Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	2.32M
Durchschnittsvolumen	2.44M
Marktkapitalisierung	182.98M
EPS	$0 ( 2024-02-08 )
Nächstes Ertragsdatum	( $-0.0600 ) 2024-05-09
Last Dividend	$0.0700 ( 2014-04-28 )
Next Dividend	$0 ( N/A )
P/E	-1.790
ATR14	$0.00800 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-02	Rankowitz Michael L	Buy	90 000	Common Stock Option
2023-10-02	Eisenberger Mario	Buy	70 000	Common Stock Option
2023-10-02	Lu Lucy	Buy	80 000	Common Stock Option
2023-10-02	Hyun Grace	Buy	60 000	Common Stock Option
2023-05-09	Greco Michele	Buy	104 000	Common Stock Option

INSIDER POWER
94.71
Last 100 transactions
Buy: 7 521 942 \| Sell: 795 000

Volumen Korrelation

Lang: -0.34 (neutral)

Kurz: -0.83 (strong negative)

Signal:(47.799) Neutral

Veru Inc Korrelation

10 Am meisten positiv korreliert
AGLE	0.927
CNSP	0.911
STER	0.91
PRTK	0.91
AZYO	0.906
TCX	0.895
TTGT	0.894
HCDIP	0.891
TFFP	0.885
INTZ	0.879

10 Am meisten negativ korreliert
LWAC	-0.95
FANH	-0.894
AGFS	-0.892
IMRA	-0.883
TGLS	-0.867
PTMN	-0.864
USLB	-0.862
LYTS	-0.859
SLGN	-0.856
SEDG	-0.852

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Veru Inc Korrelation - Währung/Rohstoff

0.70
( moderate )

0.67
( moderate )

0.00
( neutral )

-0.45
( neutral )

Veru Inc Finanzdaten

Annual	2023
Umsatz:	$16.30M
Bruttogewinn:	$7.57M (46.43 %)
EPS:	$-1.100

FY	2023
Umsatz:	$16.30M
Bruttogewinn:	$7.57M (46.43 %)
EPS:	$-1.100

FY	2022
Umsatz:	$39.35M
Bruttogewinn:	$30.59M (77.73 %)
EPS:	$-1.050

FY	2021
Umsatz:	$61.26M
Bruttogewinn:	$47.93M (78.24 %)
EPS:	$0.100

Financial Reports:

No articles found.

Veru Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Veru Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0500	2010-01-27
Last Dividend	$0.0700	2014-04-28
Next Dividend	$0	N/A
Payout Date	2014-05-07
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$1.040	--
Avg. Dividend % Per Year	0.00%	--
Score	1.68	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

1.68

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0.200	4.14%
2011	$0.200	3.50%
2012	$0.230	4.87%
2013	$0.270	3.69%
2014	$0.140	1.67%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-4.05	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.801	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.14	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.21	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.58	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.44	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.133	-1.500	7.78	-10.00	[0 - 0.6]
interestCoverageTTM	-36.67	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.591	2.00	-0.197	-0.394	[0 - 30]
freeCashFlowPerShareTTM	-0.595	2.00	-0.298	-0.595	[0 - 20]
debtEquityRatioTTM	0.208	-1.500	9.17	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.503	1.000	4.95	4.95	[0.2 - 0.8]
operatingProfitMarginTTM	-3.96	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-5.53	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.198	0.800	-2.02	-1.612	[0.5 - 2]
Total Score				-1.265

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.980	1.000	-0.301	0	[1 - 100]
returnOnEquityTTM	-2.14	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.595	2.00	-0.198	-0.595	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.591	2.00	-0.197	-0.394	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.416	1.500	-0.561	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.74	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.19

Veru Inc

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.